Research programme: CD40 inhibitors - Apoxis
Latest Information Update: 23 Nov 2006
At a glance
- Originator Apoxis
- Mechanism of Action CD40 antigen inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 23 Nov 2006 No development reported - Preclinical for Immunological disorders in Switzerland (unspecified route)
- 28 Jun 2004 Preclinical trials in Immunological disorders in Switzerland (unspecified route)